These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 23585493)
1. Any room left for new antiplatelet agents in acute coronary syndrome? Collet JP; Montalescot G Eur Heart J; 2013 Jun; 34(23):1699-701. PubMed ID: 23585493 [No Abstract] [Full Text] [Related]
2. Clinical overview of promising nonthienopyridine antiplatelet agents. Angiolillo DJ; Guzman LA Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683 [TBL] [Abstract][Full Text] [Related]
3. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022 [TBL] [Abstract][Full Text] [Related]
4. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014 [TBL] [Abstract][Full Text] [Related]
5. Advances in antiplatelet therapy for ACS and PCI. Moliterno DJ J Interv Cardiol; 2008 Dec; 21 Suppl 1():S18-24. PubMed ID: 19090933 [TBL] [Abstract][Full Text] [Related]
6. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Held C; Tricoci P; Huang Z; Van de Werf F; White HD; Armstrong PW; Ambrosio G; Aylward PE; Moliterno DJ; Wallentin L; Chen E; Erkan A; Jiang L; Strony J; Harrington RA; Mahaffey KW Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):246-56. PubMed ID: 24627331 [TBL] [Abstract][Full Text] [Related]
7. [Novel agents in antiplatelet therapy]. Ağırbaşlı M; Güvenç H; Cinçin A Turk Kardiyol Dern Ars; 2010 Jul; 38(5):369-78. PubMed ID: 21200111 [TBL] [Abstract][Full Text] [Related]
8. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. TRA*CER Executive and Steering Committees Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853 [TBL] [Abstract][Full Text] [Related]
9. [Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy]. Marcucci R G Ital Cardiol (Rome); 2010 Jun; 11(6):481-7; discussion 487. PubMed ID: 20922874 [No Abstract] [Full Text] [Related]
10. Antiplatelet therapy: no benefit of antiplatelet pretreatment in patients with NSTE-ACS. Lim GB Nat Rev Cardiol; 2015 Jan; 12(1):4. PubMed ID: 25403782 [No Abstract] [Full Text] [Related]
11. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242 [TBL] [Abstract][Full Text] [Related]
12. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866 [TBL] [Abstract][Full Text] [Related]
13. Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? Heras M; del Río A Am J Cardiovasc Drugs; 2009; 9 Suppl 1():13-7. PubMed ID: 20000883 [TBL] [Abstract][Full Text] [Related]
14. New antiplatelet agents: why they are needed. Franchini M; Mannucci PM Eur J Intern Med; 2009 Dec; 20(8):733-8. PubMed ID: 19892299 [TBL] [Abstract][Full Text] [Related]
15. Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar. Baker NC; Lipinski MJ; Lhermusier T; Waksman R Circulation; 2014 Oct; 130(15):1287-94. PubMed ID: 25287768 [No Abstract] [Full Text] [Related]